Catalent Pharma extends oral controlled release development capabilities

Catalent said that this expansion will enable the company to offer formulation development and optimisation services in its Winchester, Kentucky facility and complements that site’s existing pilot scale and commercial capabilities for controlled release tablets and capsules.

The addition of formulation development and optimisation services in Winchester will allow products to move through the development stages to commercialisation within the same site; reducing the need for additional technology transfers and facilitating a faster time to market and will also builds upon Catalent’s existing controlled release development capabilities in Somerset, New Jersey and Schorndorf, Germany.

This new formulation and process development area is expected to be open for business in early December.

Catalent Modified Release Technology business president Ian Muir said this latest investment in their modified release group continues long established heritage in this field and offers customers a more comprehensive service at Winchester facility and across their network.

A major expansion of development and commercial capabilities in Catalent’s Schorndorf, Germany oral controlled release facility is also underway for a planned launch in 2012.